

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {PACKAGE CONTAINING  
24x SYRINGES & PACKAGE CONTAINING 120x SYRINGES}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Multishield DC Intramammary Suspension for Cattle

**2. STATEMENT OF ACTIVE SUBSTANCES**

Neomycin 70 000 IU (100 mg Neomycin Sulphate) per syringe  
Penethamate 77.2 mg (100 mg Penethamate Hydriodide) per syringe  
Benzylpenicillin 227.2 mg (400 mg Procaine Benzylpenicillin) per syringe

**3. PACKAGE SIZE**

24 syringes  
120 syringes

**4. TARGET SPECIES**

Cattle (cows at drying off)

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intramammary use.

**7. WITHDRAWAL PERIODS**

Withdrawal period:  
Meat and Offal: 28 days.  
Milk: 96 hours post calving in cows with a dry period of more than 50 days.  
50 days + 96 hours after treatment from cows with a dry period of 50 days or less.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

## **9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25°C.  
Do not refrigerate or freeze.

## **10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

## **11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

## **13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited

## **14. MARKETING AUTHORISATION NUMBER**

Vm 50146/4005

## **15. BATCH NUMBER**

Lot:

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {SYRINGE LABEL}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Multishield DC Intramammary Suspension for Cattle

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Neomycin 70 000 IU (100 mg Neomycin Sulphate) per syringe  
Penethamate 77.2 mg (100 mg Penethamate Hydriodide) per syringe  
Benzylpenicillin 227.2 mg (400 mg Procaine Benzylpenicillin) per syringe

**3. BATCH NUMBER**

Lot

**4. EXPIRY DATE**

Exp.

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Multishield DC Intramammary Suspension for Cattle

#### **2. Composition**

Each 4.5 g syringe contains:

Neomycin	70 000 IU (equivalent to Neomycin Sulphate	100 mg)
Penethamate	77.2 mg (equivalent to Penethamate Hydriodide	100 mg)
Benzylopenicillin	227.2 mg (equivalent to Procaine Benzylopenicillin	400 mg)

A smooth off-white oily suspension.

#### **3. Target species**

Cattle (cows at drying off).

#### **4. Indications for use**

Treatment of subclinical mastitis caused by bovine mastitis microorganisms susceptible to the combination of active substances, penicillin and neomycin, and as part of strategy for the prevention of new infections occurring during the dry period.

#### **5. Contraindications**

Do not use in lactating cows.

Do not use in cases of hypersensitivity to the active substances,  $\beta$ -lactam antibiotics, cephalosporin antibiotics, neomycin or other aminoglycoside antibiotics or to any of the excipients.

Do not use in cows with clinical mastitis.

#### **6. Special warnings**

Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

The therapeutic efficacy of the veterinary medicinal product is only established against pathogens that are susceptible to the active substances.

Serious acute mastitis [potentially lethal] due to pathogens like *Pseudomonas aeruginosa*, can occur after drying off despite preventive treatment. Good aseptic practices should be thoroughly respected in order to reduce that risk; cows should be housed in a hygienic paddock far from the milking parlour and regularly checked several days after drying off.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to benzylpenicillin and may decrease the effectiveness of treatment with other beta lactam antimicrobials (penicillins and cephalosporins) due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Persons administering the veterinary medicinal product should avoid contact with this preparation as occasionally skin allergy may occur.

Penicillins and cephalosporins may cause sensitisation following injection, inhalation, ingestion or skin contact. Sensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

People with known hypersensitivity to  $\beta$ -lactam antibiotics, cephalosporin antibiotics, neomycin or other aminoglycoside antibiotics should avoid contact with the veterinary medicinal product.

If you develop symptoms such as a skin rash following exposure, seek medical advice and show this package leaflet or the label to the physician. Swelling of the face, lips or eyes, or difficulty with breathing are more serious symptoms and require urgent medical attention.

Pregnancy and lactation:

The use is not recommended during lactation, except at the drying off stage

Interaction with other medicinal products and other forms of interaction:

No data available.

Overdose:

Overdosing may invalidate the stated milk and meat withdrawal times.

## 7. Adverse events

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Allergic reactions (allergic skin reactions, anaphylaxis)<sup>1</sup>

Hypersensitivity<sup>1</sup>

<sup>1</sup>May occasionally be serious. If adverse reactions occur, the current treatment should be withdrawn and symptomatic treatment should be initiated.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Intramammary use.

Dose: 100 mg of neomycin sulphate, 100 mg of Penethamate Hydriodide and 400 mg of Procaine Benzylpenicillin into each quarter.

The contents of one syringe should be infused into each quarter via the teat canal immediately after the final milking of a lactation.

## **9. Advice on correct administration**

Before instillation, the udder should be milked out completely. The teat and its orifice should be thoroughly cleaned and disinfected with a cleaning towel. Care should be taken to avoid contamination of the injector nozzle. Gently insert the content of one syringe into each quarter. Disperse the veterinary medicinal product by gentle massage of the teat and udder. The syringe must only be used once.

## **10. Withdrawal periods**

Meat and Offal: 28 days.

Milk: 96 hours post calving in cows with a dry period of more than 50 days.

50 days plus 96 hours after treatment from cows with a dry period of 50 days or less.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 25°C.

Do not refrigerate or freeze.

For single use only.

Do not use this veterinary medicinal product after the expiry date which is stated on the syringe label, and bucket label after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 50146/4005

### Pack sizes:

Bucket containing 24 syringes.

Bucket containing 120 syringes.

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

### Marketing authorisation holder and manufacturer responsible for batch release:

Bimeda Animal Health Limited  
2 / 3 / 4 Airton Close  
Tallaght  
Dublin 24  
Ireland

### Local representatives and contact details to report suspected adverse reactions:

Cross Vetpharm Group UK Limited (Trading as Bimeda)  
Unit 2, Bryn Cefni Industrial Park

Llangefni  
LL77 7XA  
United Kingdom  
Tel: 01248 725 400

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## **17. Other information**

POM-V

*Gavin Hall*  
Approved: 16 April 2025